Theracurmin (Nano-Curcumin) for ALS
Also known as: Nano-curcumin, Highly bioavailable curcumin
Enhanced curcumin delivery may enable anti-neuroinflammatory effects in ALS motor cortex and spinal cord.
Mechanism of Action
Theracurmin delivers bioavailable curcumin to inhibit NF-κB-driven neuroinflammation, reduce microglial activation, and support mitochondrial function in motor neurons.
General mechanism: Nano-encapsulated curcumin with 27x bioavailability. NF-κB inhibitor, anti-amyloid, anti-tau, Nrf2 activator at achievable tissue levels.
Current Evidence
No ALS-specific studies. AD bioavailability and biomarker data support investigation for other neurodegenerative conditions.
Clinical Status: No ALS trials. Rationale from AD bioavailability data.
Safety Profile
Safe. Well-tolerated in clinical trials. Same safety profile as standard curcumin with enhanced absorption.
Key Research Questions
- Can Theracurmin reach motor neurons at anti-inflammatory concentrations?
- Would enhanced curcumin bioavailability benefit ALS neuroinflammation?